1. Introduction

On November 1-2, 2005, the Food and Drug Administration (FDA) hosted a 2-day public hearing to provide an opportunity for broad public participation and comment on direct-to-consumer (DTC) promotion of regulated medical products, including prescription drugs for humans and animals, vaccines, blood products, and medical devices.

Regarding the educational merits of DTC advertising, FDA wanted to know if DTC needs additional educational content about the disease or condition. "FDA is ... specifically interested in whether paying greater attention to the educational component of an advertisement (i.e., devoting more attention to defining the disease and its manifestations) would help consumers better understand the role drug and device therapy may play in treating that disease."

Regarding the presentation of risk information in DTC ads, the FDA "is interested in hearing why consumers and healthcare providers may believe that risk information is not being communicated as clearly as benefit information, even though that information is present."

This survey asks your opinions regarding the DTC issues discussed at this FDA public hearing. These value-related issues are as pertinent today as they were in 2005.

Your responses are confidential. At the end of the survey, you can access the de-identified up-to-date results.